ClinicalTrials.gg
CompletedNCT05099159Updated Feb 12, 2026Results posted

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)

A Phase 3 interventional study of Elinzanetant (BAY3427080) and Placebo in Vasomotor Symptoms Associated With Menopause and Hot Flashes, sponsored by Bayer. Completed at 113 sites in 12 countries. Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-12.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing elinzanetant in Hot Flashes — none open to participants now, 1 under way, 1 of them phase 3. elinzanetant · Hot Flashes.

Enrollment
3rd of 13
400 · median 64
Started
2021
with 4 others
Phase 3
4 of 13
none open now
Registered
7th of 13
by date
Lead sponsor
13 of 13
Bayer

Among the 13 studies testing elinzanetant in Hot Flashes, this one is the 3rd largest by enrollment, is one of 5 that started in 2021, is one of 4 in phase 3, and was the 7th registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

None of the 13 studies testing elinzanetant in Hot Flashes is open now. The open studies under Hot Flashes, anywhere →

About elinzanetant

elinzanetant: first FDA approval 2025 (LYNKUET), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 40 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing elinzanetant in Hot Flashes as a file.
02

Study summary

Researchers are looking for a better way to treat women who have hot flashes after women have been through the menopause. Hot flashes are caused by the hormonal changes that happen when a woman's body has been through the menopause. Menopause is when women stop having a menstrual cycle, also called a period. During the menopause, the ovaries increasingly produce less sex hormones as a result of the natural ageing process and related hormonal adjustments. The decline in hormone production can lead to various symptoms which, in some cases, can have a very adverse effect on a menopausal woman's quality of life.

The study treatment, elinzanetant, was developed to treat symptoms caused by hormonal changes. It works by blocking a protein called neurokinin from sending signals to other parts of the body, which is thought to play a role in starting hot flashes. There are treatments for hot flashes in women who have been through the menopause, but may cause medical problems for some people.

In this study, the researchers will learn how well elinzanetant works compared to a placebo in women who have been through the menopause and have hot flashes. A placebo looks like a treatment but does not have any medicine in it. To compare these study treatments, the doctors will ask the participants to record information about the participants' hot flashes in an electronic diary. The researchers will study the number of hot flashes the participants have and how severe the hot flashes are. The researchers will look at the results from before treatment, after 4 weeks, and after 12 weeks of treatment.

The participants in this study will take two capsules of either elinzanetant or the placebo once a day. The participants who take elinzanetant will take it for 26 weeks. The participants who take the placebo will take it for 12 weeks and then take elinzanetant for the next 14 weeks.

During the study, the participants will visit the site approximately 9 times and perform 1 visit by phone. Each participant will be in the study for approximately 36 weeks. The treatment duration will be 26 weeks.

During the study, the participants will:

  • record information about the participants' hot flashes in an electronic diary
  • answer questions about the participants' symptoms

The doctors will:

  • check the participants' health
  • take blood samples
  • ask the participants questions about what medicines the participants are taking and if the participants are having adverse events An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if doctors do not think the adverse events might be related to the study treatments.
03

Conditions studied

  • Vasomotor Symptoms Associated With Menopause
  • Hot Flashes

Browse trials for

Keywords

  • Menopause
04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • , defined as:

    1. at least 12 months of spontaneous amenorrhea prior to signing of , or
    2. at least 6 months of spontaneous amenorrhea prior to signing of informed consent with serum follicle-stimulating hormone (FSH) levels > 40 mIU/mL and a serum estradiol concentration of \< 30 pg/mL, or
    3. at least 6 months after hysterectomy at signing of informed consent with serum FSH levels > 40 mIU/mL and a serum estradiol concentration of \< 30 pg/mL, or
    4. surgical bilateral oophorectomy with or without hysterectomy at least 6 weeks prior to signing of informed consent.
  • Moderate to severe hot flash (HF) associated with the menopause and seeking treatment for this condition.
  • Participant has completed Hot Flash Daily Diary (HFDD) for at least 11 days during the two weeks preceding baseline visit, and participant has recorded at least 50 moderate or severe HF (including night-time HF) over the last 7 days that the HFDD was completed (assessed at the Baseline Visit).

Exclusion criteria

Exclusion Criteria:

  • Any prior or ongoing history of arrhythmias, heart block and either determined through clinical history or on evaluation.
  • Any active ongoing condition that could cause difficulty in interpreting vasomotor symptoms (VMS) such as: infection that could cause pyrexia, pheochromocytoma, carcinoid syndrome.
  • Current or history (except complete remission for 5 years or more) of any (except basal and squamous cell skin tumors). Women receiving endocrine therapy (e.g. tamoxifen, aromatase inhibitors, GnRH analogues) cannot be enrolled in this study.
  • Uncontrolled or treatment-resistant hypertension. Women with mild hypertension can be included in the study if they are medically cleared prior to study participation.
  • Untreated hyperthyroidism or hypothyroidism.

    • Treated hyperthyroidism with no abnormal increase of thyroid function laboratory parameters and no relevant clinical signs for > 6 months before signing of is acceptable.
    • Treated hypothyroidism with normal thyroid function test results during screening and a stable (for ≥ 3 months before signing of informed consent) dose of replacement therapy is acceptable.
  • Any unexplained uterine bleeding.
  • Clinically relevant abnormal findings on mammogram.
  • Abnormal liver parameters.
  • Disordered proliferative endometrium, endometrial hyperplasia, polyp, or endometrial cancer diagnosed based on endometrial during screening.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
400 participants (actual)

Study arms

  • Experimental
    Elinzanetant (BAY3427080)

    Participants will receive 120 mg elinzanetant orally once daily for 26 weeks.

    Drug: Elinzanetant (BAY3427080)

  • Placebo comparator
    Placebo + elinzanetant

    Participants will receive matching placebo orally once daily for 12 weeks, followed by elinzanetant 120 mg for 14 weeks.

    Drug: Elinzanetant (BAY3427080) · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 4 (Assessed by HFDD)

    Participants' assessments of HF were recorded electronically twice daily using the sponsor developed Hot Flash Daily Diary (HFDD). The HFDD was completed in the morning after waking up (morning diary) and each evening at bedtime (evening diary) on the hand-held device. The HFDD items assessed the number of mild, moderate, and severe HF experienced during the day and during the night. Mild HF was defined as a "sensation of heat without sweating", moderate HF was defined as a "sensation of heat with sweating, but able to continue activity", and severe HF was defined as a "sensation of heat with sweating, causing cessation (stopping) of activity". The frequency of moderate to severe HF for each week during the treatment period was calculated using the available data during that particular week. Specifically, for Week 4, Day 22-28 were used (Day 1 corresponds to start of treatment).

    Time frame: From baseline to Week 4

  2. Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 12 (Assessed by HFDD)

    The frequency of moderate to severe HF for each week during the treatment period was calculated using the available data during that particular week. Specifically, for Week 12, Day 78-84 were used (Day 1 corresponds to start of treatment).

    Time frame: From baseline to Week 12

  3. Mean Change in Severity of Moderate to Severe HF From Baseline to Week 4 (Assessed by HFDD)

    In the HFDD, hot flash (HF) severity is scored as 1=mild, 2=moderate, and 3=severe; a decrease indicates improvement. The diary records the number of mild, moderate, and severe HFs during day and night. Mild HFs are a "sensation of heat without sweating"; moderate are "heat with sweating but able to continue activity"; severe are "heat with sweating that stops activity." Baseline mean daily severity is calculated as: (2×moderateHFs+3×severeHFs)÷(totalmoderate+severeHFs).(2 × moderate HFs + 3 × severe HFs) ÷ (total moderate + severe HFs).(2×moderateHFs+3×severeHFs)÷(totalmoderate+severeHFs). If none occur, severity=0. Weekly severity during treatment is based on available days (Week 4: Days 22-28; Week 12: Days 78-84; Day 1=start of treatment), averaging the mean daily severity for that week. If more than 2 days are missing, the weekly value is set to missing

    Time frame: From baseline to Week 4

  4. Mean Change in Severity of Moderate to Severe HF From Baseline to Week 12 (Assessed by HFDD)

    In the HFDD, hot flash (HF) severity is categorized as 1=mild, 2=moderate, 3=severe; thus, a decrease indicates improvement. The HFDD records the number of mild, moderate, and severe HFs during day and night. Mild HFs are a "sensation of heat without sweating"; moderate involve "heat with sweating but able to continue activity"; severe involve "heat with sweating that stops activity." Mean daily severity at baseline is calculated as: (2 × moderate HFs) + (3 × severe HFs)\\\] ÷ (total moderate + severe HFs). If none occur, severity is set to 0. Weekly severity during treatment is based on available days (Week 4: Days 22-28; Week 12: Days 78-84; Day 1=start of treatment), averaging mean daily severity across that week. If more than 2 days are missing, the week is set to missing.

    Time frame: From baseline to Week 12

Secondary outcomes

  1. Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 1 (Assessed by HFDD)

    Participants' assessments of HF were recorded electronically twice daily using the sponsor developed HFDD. The HFDD was completed in the morning after waking up (morning diary) and each evening at bedtime (evening diary) on the hand-held device.

    Time frame: From baseline to Week 1

  2. Mean Change in Frequency of Moderate to Severe HF From Baseline Over Time (Assessed by HFDD)

    The frequency of moderate to severe HF for each week during the treatment period was calculated using the available data during that particular week. Specifically, for Week 1 Days 2-8 were used instead of 1-7, because the intake started on Day 1 only before going to bed, for Week 4 Days 22-28 were used and for Week 12 Days 78-84 were used (Day 1 corresponds to start of treatment). These data were aggregated to a mean daily frequency as (total number of moderate to severe HF during that week) / (total number of available days with data during that week). In case data is not available for more than 2 days within a week, the value for that particular week was be set to missing.

    Time frame: From baseline to Week 30

  3. Mean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score From Baseline to Week 12

    In controversy of what you have been proposing above here you are just explaining the PROMIS SD SF 8b scores, not the secondary endpoint which is the change in the T-scores from BL to week 12 The PROMIS Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) measures sleep disturbance over the past 7 days using 8 items assessing sleep quality, depth, restorative sleep, difficulty falling or staying asleep, and perceptions of sleep adequacy and satisfaction. Items use 5-point response options that vary by item (e.g., Not at all → Very much; Never → Always; Very poor → Very good). Item scores sum to a raw score of 8-40, which is converted to a T-score (mean 50, SD 10; range 28.9-76.5). Higher scores reflect greater sleep disturbance. PROMIS cut points classify T-scores of 55-59 as mild, 60-69 as moderate, and ≥70 as severe disturbance.

    Time frame: From baseline to Week 12

  4. Mean Change in Menopause-specific Quality of Life Scale (MENQOL) Total Score From Baseline to Week 12

    The MENQOL questionnaire was comprised of 29 items assessing the presence of menopausal symptoms and the impact of menopause on health-related quality of life over the past week. The items assessed four domains of symptoms and functioning: VMS, psychosocial functioning, physical functioning, and sexual functioning. For each item, the participants indicated if they had experienced the symptom (yes/no). If participants selected yes, participants rated how bothered they were by the symptom using a six-point verbal descriptor scale, with response options ranging from 0 'not at all bothered' to 6 'extremely bothered'. Based on the individual responses, item scores, domain scores, and a total MENQOL score were calculated. The four domain scores were calculated as a mean of converted single item scores (range 1-8), and the mean of the four domain scores yielded the MENQOL total score. Higher scores indicated greater bother.

    Time frame: From baseline to Week 12

  5. Mean Change in Beck Depression Inventory (BDI-II) Total Score From Baseline to Week 12

    The BDI-II consisted of 21 items to assess the severity of depression over the past 2 weeks. Each item was a list of four statements arranged in increasing levels of severity about a particular symptom of depression. Items used a 4-point verbal response scale ranging from 0 (not at all) to 3 (extreme form of each symptom); specific response options were tailored to the aspect of depression being measured in each item. A total score ranging from 0 to 63 was calculated with scores of 0-13 indicating mild minimal range, 14 - 19 indicating mild depression, 20 - 28 indicating moderate and 29 - 63 indicating severe depression (higher score = greater depression).

    Time frame: From baseline to Week 12

  6. Mean Change in BDI-II Total Score From Baseline to Week 26

    The BDI-II consisted of 21 items to assess the severity of depression over the past 2 weeks. Each item was a list of four statements arranged in increasing levels of severity about a particular symptom of depression. Items used a 4-point verbal response scale ranging from 0 (not at all) to 3 (extreme form of each symptom); specific response options were tailored to the aspect of depression being measured in each item. A total score ranging from 0 to 63 was calculated with scores of 0-13 indicating mild minimal range, 14 - 19 indicating mild depression, 20 - 28 indicating moderate and 29 - 63 indicating severe depression (higher score = greater depression).

    Time frame: From baseline to Week 26

07

Results

Posted Feb 12, 2026

Participant flow

Study was conducted at 95 study centers in 10 countries worldwide, between 29-Oct-2021 (first participant first visit) and 10-Oct-2023 (last participant last visit).

Participant flow — Overall Study
MilestoneElinzanetant 120 mgPlacebo - Elinzanetant 120 mg
Started200200
Completed157167
Not completed4333
Withdrew: Subject decision1410
Withdrew: Adverse event73
Withdrew: Lack of efficacy11
Withdrew: Lost to follow-up61
Withdrew: Non-compliance with study drug14
Withdrew: Other11
Withdrew: Protocol violation01
Withdrew: Did not complete study treatment but completed fu1312

Outcome measures

PrimaryMean Change in Frequency of Moderate to Severe HF From Baseline to Week 4 (Assessed by HFDD)

Participants' assessments of HF were recorded electronically twice daily using the sponsor developed Hot Flash Daily Diary (HFDD). The HFDD was completed in the morning after waking up (morning diary) and each evening at bedtime (evening diary) on the hand-held device. The HFDD items assessed the number of mild, moderate, and severe HF experienced during the day and during the night. Mild HF was defined as a "sensation of heat without sweating", moderate HF was defined as a "sensation of heat with sweating, but able to continue activity", and severe HF was defined as a "sensation of heat with sweating, causing cessation (stopping) of activity". The frequency of moderate to severe HF for each week during the treatment period was calculated using the available data during that particular week. Specifically, for Week 4, Day 22-28 were used (Day 1 corresponds to start of treatment).

Time frame:
From baseline to Week 4
Reported as:
Mean · Hot Flashes per day
Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 4 (Assessed by HFDD)
Hot Flashes per dayElinzanetant 120 mgPlacebo - Elinzanetant 120 mg
Baseline14.66 ± 11.0816.16 ± 11.15
Change from Baseline-8.58 ± 9.16-6.07 ± 8.91
Statistical analysis
  • Elinzanetant 120 mg vs Placebo - Elinzanetant 120 mg · Mixed model repeated measures (MMRM) · p = < 0.0001 (One-sided. A multiplicity adjustment strategy was defined using the graphical approach, controlling the overall type I error rate at a one-sided alpha level of 0.025 for confirmatory statistical superiority testing.) · Least squares (ls) means: -3.04 · 95% CI -4.40 to -1.68
PrimaryMean Change in Frequency of Moderate to Severe HF From Baseline to Week 12 (Assessed by HFDD)

The frequency of moderate to severe HF for each week during the treatment period was calculated using the available data during that particular week. Specifically, for Week 12, Day 78-84 were used (Day 1 corresponds to start of treatment).

Time frame:
From baseline to Week 12
Reported as:
Mean · Hot flashes per day
Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 12 (Assessed by HFDD)
Hot flashes per dayElinzanetant 120 mgPlacebo - Elinzanetant 120 mg
Baseline14.66 ± 11.0816.16 ± 11.15
Change from Baseline-9.96 ± 10.25-7.24 ± 8.49
Statistical analysis
  • Elinzanetant 120 mg vs Placebo - Elinzanetant 120 mg · MMRM · p = < 0.0001 (One-sided. A multiplicity adjustment strategy was defined using the graphical approach, controlling the overall type I error rate at a one-sided alpha level of 0.025 for confirmatory statistical superiority testing.) · Ls-means: -3.24 · 95% CI -4.60 to -1.88
PrimaryMean Change in Severity of Moderate to Severe HF From Baseline to Week 4 (Assessed by HFDD)

In the HFDD, hot flash (HF) severity is scored as 1=mild, 2=moderate, and 3=severe; a decrease indicates improvement. The diary records the number of mild, moderate, and severe HFs during day and night. Mild HFs are a "sensation of heat without sweating"; moderate are "heat with sweating but able to continue activity"; severe are "heat with sweating that stops activity." Baseline mean daily severity is calculated as: (2×moderateHFs+3×severeHFs)÷(totalmoderate+severeHFs).(2 × moderate HFs + 3 × severe HFs) ÷ (total moderate + severe HFs).(2×moderateHFs+3×severeHFs)÷(totalmoderate+severeHFs). If none occur, severity=0. Weekly severity during treatment is based on available days (Week 4: Days 22-28; Week 12: Days 78-84; Day 1=start of treatment), averaging the mean daily severity for that week. If more than 2 days are missing, the weekly value is set to missing

Time frame:
From baseline to Week 4
Reported as:
Mean · Units on a scale
Mean Change in Severity of Moderate to Severe HF From Baseline to Week 4 (Assessed by HFDD)
Units on a scaleElinzanetant 120 mgPlacebo - Elinzanetant 120 mg
Baseline2.53 ± 0.242.54 ± 0.24
Change from Baseline-0.75 ± 0.68-0.53 ± 0.55
Statistical analysis
  • Elinzanetant 120 mg vs Placebo - Elinzanetant 120 mg · MMRM · p = 0.0003 (One-sided. A multiplicity adjustment strategy was defined using the graphical approach, controlling the overall type I error rate at a one-sided alpha level of 0.025 for confirmatory statistical superiority testing.) · Ls-means: -0.22 · 95% CI -0.34 to -0.09
PrimaryMean Change in Severity of Moderate to Severe HF From Baseline to Week 12 (Assessed by HFDD)

In the HFDD, hot flash (HF) severity is categorized as 1=mild, 2=moderate, 3=severe; thus, a decrease indicates improvement. The HFDD records the number of mild, moderate, and severe HFs during day and night. Mild HFs are a "sensation of heat without sweating"; moderate involve "heat with sweating but able to continue activity"; severe involve "heat with sweating that stops activity." Mean daily severity at baseline is calculated as: (2 × moderate HFs) + (3 × severe HFs)\\\] ÷ (total moderate + severe HFs). If none occur, severity is set to 0. Weekly severity during treatment is based on available days (Week 4: Days 22-28; Week 12: Days 78-84; Day 1=start of treatment), averaging mean daily severity across that week. If more than 2 days are missing, the week is set to missing.

Time frame:
From baseline to Week 12
Reported as:
Mean · Units on a scale
Mean Change in Severity of Moderate to Severe HF From Baseline to Week 12 (Assessed by HFDD)
Units on a scaleElinzanetant 120 mgPlacebo - Elinzanetant 120 mg
Baseline2.53 ± 0.242.54 ± 0.24
Change from baseline-0.97 ± 0.78-0.65 ± 0.67
Statistical analysis
  • Elinzanetant 120 mg vs Placebo - Elinzanetant 120 mg · MMRM · p = <0.0001 (One-sided. A multiplicity adjustment strategy was defined using the graphical approach, controlling the overall type I error rate at a one-sided alpha level of 0.025 for confirmatory statistical superiority testing.) · Ls-means: -0.29 · 95% CI -0.44 to -0.14
SecondaryMean Change in Frequency of Moderate to Severe HF From Baseline to Week 1 (Assessed by HFDD)

Participants' assessments of HF were recorded electronically twice daily using the sponsor developed HFDD. The HFDD was completed in the morning after waking up (morning diary) and each evening at bedtime (evening diary) on the hand-held device.

Time frame:
From baseline to Week 1
Reported as:
Mean · Hot flashes per day
Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 1 (Assessed by HFDD)
Hot flashes per dayElinzanetant 120 mgPlacebo - Elinzanetant 120 mg
Baseline14.66 ± 11.0816.16 ± 11.15
Change from baseline-4.66 ± 6.70-3.57 ± 6.86
Statistical analysis
  • Elinzanetant 120 mg vs Placebo - Elinzanetant 120 mg · MMRM · p = 0.0013 (One-sided. A multiplicity adjustment strategy was defined using the graphical approach, controlling the overall type I error rate at a one-sided alpha level of 0.025 for confirmatory statistical superiority testing.) · Ls-means: -1.66 · 95% CI -2.73 to -0.58
SecondaryMean Change in Frequency of Moderate to Severe HF From Baseline Over Time (Assessed by HFDD)

The frequency of moderate to severe HF for each week during the treatment period was calculated using the available data during that particular week. Specifically, for Week 1 Days 2-8 were used instead of 1-7, because the intake started on Day 1 only before going to bed, for Week 4 Days 22-28 were used and for Week 12 Days 78-84 were used (Day 1 corresponds to start of treatment). These data were aggregated to a mean daily frequency as (total number of moderate to severe HF during that week) / (total number of available days with data during that week). In case data is not available for more than 2 days within a week, the value for that particular week was be set to missing.

Time frame:
From baseline to Week 30
Reported as:
Mean · Hot flashes per day
Mean Change in Frequency of Moderate to Severe HF From Baseline Over Time (Assessed by HFDD)
Hot flashes per dayElinzanetant 120 mgPlacebo - Elinzanetant 120 mg
Baseline14.66 ± 11.0816.16 ± 11.15
Change from baseline to Week 1-4.66 ± 6.70-3.57 ± 6.86
Change from baseline to Week 4-8.58 ± 9.16-6.07 ± 8.91
Change from baseline to Week 8-9.67 ± 10.02-6.91 ± 9.07
Change from baseline to Week 12-9.96 ± 10.25-7.24 ± 8.49
Change from baseline to Week 16-10.96 ± 11.55-10.89 ± 9.54
Change from baseline to Week 20-11.60 ± 11.54-11.26 ± 9.31
Change from baseline to Week 26-11.76 ± 11.38-12.76 ± 12.28
Change from baseline to Week 30-7.90 ± 11.68-9.36 ± 11.71
SecondaryMean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score From Baseline to Week 12

In controversy of what you have been proposing above here you are just explaining the PROMIS SD SF 8b scores, not the secondary endpoint which is the change in the T-scores from BL to week 12 The PROMIS Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) measures sleep disturbance over the past 7 days using 8 items assessing sleep quality, depth, restorative sleep, difficulty falling or staying asleep, and perceptions of sleep adequacy and satisfaction. Items use 5-point response options that vary by item (e.g., Not at all → Very much; Never → Always; Very poor → Very good). Item scores sum to a raw score of 8-40, which is converted to a T-score (mean 50, SD 10; range 28.9-76.5). Higher scores reflect greater sleep disturbance. PROMIS cut points classify T-scores of 55-59 as mild, 60-69 as moderate, and ≥70 as severe disturbance.

Time frame:
From baseline to Week 12
Reported as:
Mean · Scores on a scale
Mean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score From Baseline to Week 12
Scores on a scaleElinzanetant 120 mgPlacebo - Elinzanetant 120 mg
Baseline61.7 ± 6.260.7 ± 7.2
Change from baseline-10.6 ± 7.7-5.5 ± 6.9
Statistical analysis
  • Elinzanetant 120 mg vs Placebo - Elinzanetant 120 mg · MMRM · p = <0.0001 (One-sided. A multiplicity adjustment strategy was defined using the graphical approach, controlling the overall type I error rate at a one-sided alpha level of 0.025 for confirmatory statistical superiority testing.) · Ls-means: -4.32 · 95% CI -5.77 to -2.86
SecondaryMean Change in Menopause-specific Quality of Life Scale (MENQOL) Total Score From Baseline to Week 12

The MENQOL questionnaire was comprised of 29 items assessing the presence of menopausal symptoms and the impact of menopause on health-related quality of life over the past week. The items assessed four domains of symptoms and functioning: VMS, psychosocial functioning, physical functioning, and sexual functioning. For each item, the participants indicated if they had experienced the symptom (yes/no). If participants selected yes, participants rated how bothered they were by the symptom using a six-point verbal descriptor scale, with response options ranging from 0 'not at all bothered' to 6 'extremely bothered'. Based on the individual responses, item scores, domain scores, and a total MENQOL score were calculated. The four domain scores were calculated as a mean of converted single item scores (range 1-8), and the mean of the four domain scores yielded the MENQOL total score. Higher scores indicated greater bother.

Time frame:
From baseline to Week 12
Reported as:
Mean · Scores on a scale
Mean Change in Menopause-specific Quality of Life Scale (MENQOL) Total Score From Baseline to Week 12
Scores on a scaleElinzanetant 120 mgPlacebo - Elinzanetant 120 mg
Baseline4.48 ± 1.144.49 ± 1.17
Change from baseline-1.34 ± 1.29-0.97 ± 1.16
Statistical analysis
  • Elinzanetant 120 mg vs Placebo - Elinzanetant 120 mg · MMRM · p = =0.0059 (One-sided. A multiplicity adjustment strategy was defined using the graphical approach, controlling the overall type I error rate at a one-sided alpha level of 0.025 for confirmatory statistical superiority testing.) · Ls-means: -0.30 · 95% CI -0.53 to -0.07
SecondaryMean Change in Beck Depression Inventory (BDI-II) Total Score From Baseline to Week 12

The BDI-II consisted of 21 items to assess the severity of depression over the past 2 weeks. Each item was a list of four statements arranged in increasing levels of severity about a particular symptom of depression. Items used a 4-point verbal response scale ranging from 0 (not at all) to 3 (extreme form of each symptom); specific response options were tailored to the aspect of depression being measured in each item. A total score ranging from 0 to 63 was calculated with scores of 0-13 indicating mild minimal range, 14 - 19 indicating mild depression, 20 - 28 indicating moderate and 29 - 63 indicating severe depression (higher score = greater depression).

Time frame:
From baseline to Week 12
Reported as:
Mean · Scores on a scale
Mean Change in Beck Depression Inventory (BDI-II) Total Score From Baseline to Week 12
Scores on a scaleElinzanetant 120 mgPlacebo - Elinzanetant 120 mg
Baseline6.6 ± 6.57.2 ± 6.8
Change from baseline-0.2 ± 8.30.8 ± 8.6
SecondaryMean Change in BDI-II Total Score From Baseline to Week 26

The BDI-II consisted of 21 items to assess the severity of depression over the past 2 weeks. Each item was a list of four statements arranged in increasing levels of severity about a particular symptom of depression. Items used a 4-point verbal response scale ranging from 0 (not at all) to 3 (extreme form of each symptom); specific response options were tailored to the aspect of depression being measured in each item. A total score ranging from 0 to 63 was calculated with scores of 0-13 indicating mild minimal range, 14 - 19 indicating mild depression, 20 - 28 indicating moderate and 29 - 63 indicating severe depression (higher score = greater depression).

Time frame:
From baseline to Week 26
Reported as:
Mean · Scores on a scale
Mean Change in BDI-II Total Score From Baseline to Week 26
Scores on a scaleElinzanetant 120 mgPlacebo - Elinzanetant 120 mg
Baseline6.6 ± 6.57.2 ± 6.8
Change from baseline-1.0 ± 6.9-1.1 ± 6.7

Adverse events

Collected over From the start of study medication up to 14 days after the last dose of medication, approximately 28 weeks. Adverse event reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact, approximately 30 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Elinzanetant 120mg Week 1-120/201 (0%)1/201 (0.5%)34/201 (16.9%)
Placebo Week 1-120/199 (0%)1/199 (0.5%)25/199 (12.6%)
Elinzanetant 120mg Week 13-260/171 (0%)1/171 (0.6%)5/171 (2.9%)
Placebo - Elinzanetant 120mg Week 13-260/180 (0%)3/180 (1.7%)8/180 (4.4%)
Elinzanetant 120mg Week 1-260/381 (0%)5/381 (1.3%)45/381 (11.8%)
Most frequent serious events
Most frequent serious events
EventElinzanetant 120mg Week 1-12Placebo Week 1-12Elinzanetant 120mg Week 13-26Placebo - Elinzanetant 120mg Week 13-26Elinzanetant 120mg Week 1-26
Urinary tract infectionInfections and infestations0/2010/1991/1710/1801/381
Mechanical ileusGastrointestinal disorders0/2010/1990/1711/1801/381
Joint range of motion decreasedMusculoskeletal and connective tissue disorders0/2010/1990/1711/1801/381
Generalised tonic-clonic seizureNervous system disorders0/2010/1990/1711/1801/381
Device looseningProduct Issues0/2010/1990/1711/1801/381
PyelonephritisInfections and infestations0/2011/1990/1710/1800/381
UrosepsisInfections and infestations0/2011/1990/1710/1800/381
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/2010/1990/1710/1801/381
Deep vein thrombosisVascular disorders1/2010/1990/1710/1801/381
Most frequent other events
Most frequent other events
EventElinzanetant 120mg Week 1-12Placebo Week 1-12Elinzanetant 120mg Week 13-26Placebo - Elinzanetant 120mg Week 13-26Elinzanetant 120mg Week 1-26
HeadacheNervous system disorders18/2015/1994/1714/18024/381
Depression rating scale score increasedInvestigations9/20117/1990/1712/18011/381
FatigueGeneral disorders11/2013/1991/1713/18015/381

Baseline characteristics

Full analysis set (FAS) was analyzed. FAS: all randomized subjects were included. Subjects in the full analysis set were analyzed according to the randomized intervention (intention-to-treat).

Age, Continuous
Age, Continuous(years)Elinzanetant 120 mgPlacebo - Elinzanetant 120 mgTotal
Mean54.8 ± 5.054.4 ± 4.554.6 ± 4.8
Sex: Female, Male
Sex: Female, Male(Participants)Elinzanetant 120 mgPlacebo - Elinzanetant 120 mgTotal
Female200200400
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Elinzanetant 120 mgPlacebo - Elinzanetant 120 mgTotal
Hispanic or Latino132437
Not Hispanic or Latino186175361
Unknown or Not Reported112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Elinzanetant 120 mgPlacebo - Elinzanetant 120 mgTotal
American Indian or Alaska Native112
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American352560
White163172335
More than one race011
Unknown or Not Reported101
08

Study locations

113 sites
  • Accel Research Sites | Cahaba Medical Care - Birmingham, AL
    Birmingham, Alabama 35218, United States
  • Women's Health Alliance of Mobile
    Mobile, Alabama 36604, United States
  • Onyx Clinical Research - Peoria
    Peoria, Arizona 85381, United States
  • Lynn Institute of the Ozarks
    Little Rock, Arkansas 72204, United States
  • National Institute of Clinical Research - Garden Grove
    Garden Grove, California 92844, United States
  • Clinical Trials Research - Lincoln
    Lincoln, California 95648, United States
  • Torrance Clinical Research Institute, Inc. | Lomita, CA
    Lomita, California 90717, United States
  • Women's Health Care Research | San Diego, CA
    San Diego, California 92111, United States
  • Advanced Women's Health Institute | Denver Office, Greenwood Village, CO
    Greenwood Village, Colorado 80111, United States
  • Physicians' Research Options, LLC | Red Rocks OBGYN
    Lakewood, Colorado 80228, United States
  • Helix Biomedics, LLC
    Boynton Beach, Florida 33435, United States
  • Clinical Research of West Florida | Clearwater, FL
    Clearwater, Florida 33765, United States
  • Sweet Hope Research Specialty, Inc. - Miami Lakes
    Hialeah, Florida 33016, United States
  • Ocean Blue Medical Research Center, Inc | Miami Springs, FL
    Miami Springs, Florida 33166, United States
  • Suncoast Clinical Research Inc. | Pasco
    New Port Richey, Florida 34652, United States
  • Sensible Healthcare, LLC
    Ocoee, Florida 34761, United States
  • Clinical Research of West Florida | Tampa, FL
    Tampa, Florida 33606, United States
  • Fellows Research Alliance, Inc | Savannah, GA
    Savannah, Georgia 31406, United States
  • Family Care Research | Boise, ID
    Boise, Idaho 83713, United States
  • Leavitt Clinical Research | Idaho Falls, ID
    Idaho Falls, Idaho 83404, United States
  • University of Chicago | Laboratory of Dr. Al-Hendy
    Chicago, Illinois 60637, United States
  • AMR - Chicago
    Oak Brook, Illinois 60523, United States
  • Clinical Trials Management | Northshore Office
    Covington, Louisiana 70433, United States
  • Tandem Clinical Research | Marrero, LA
    Marrero, Louisiana 70072, United States
  • Ob and Gyn Physicians MidAtlantic - SKYCRNG
    Oxon Hill, Maryland 20705, United States
  • Genesis Clinical Research and Consulting, LLC
    Fall River, Massachusetts 02723, United States
  • Saginaw Valley Medical Research Group, LLC | Saginaw, MI
    Saginaw, Michigan 48604, United States
  • Metro Jackson OBGYN | Jackson, MS
    Jackson, Mississippi 39202, United States
  • R. Garn Mabey Jr. M.D. Gynecology
    Las Vegas, Nevada 89128, United States
  • Capital Health | Capital Health OBGYN Lawrenceville
    Lawrenceville, New Jersey 08648, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Eastern Carolina Women's Center | New Bern, NC
    New Bern, North Carolina 28562, United States
  • Unified Women's Clinical Research | Raleigh, NC
    Raleigh, North Carolina 27607, United States
  • OHSU Hospital - OB-GYN - Women's Health Research Unit
    Portland, Oregon 97239, United States
  • UPMC Magee-Women's Hospital - Gynecology
    Pittsburgh, Pennsylvania 15213, United States
  • Tribe clinical Research LLC | Greenville, SC
    Greenville, South Carolina 29607, United States
  • Medical Research Center of Memphis | Memphis, TN
    Memphis, Tennessee 38120, United States
  • Research Memphis Associates, LLC | Memphis, TN
    Memphis, Tennessee 38120, United States
  • Austin Regional Clinic | ARC Kelly Lane
    Austin, Texas 78731, United States
  • DiscoveResearch, Inc.
    Bryan, Texas 77802, United States
  • South Texas Clinical Research
    Corpus Christi, Texas 78404, United States
  • Sig Gyn Services (Dr. John A. Whitfield, MD) | Fort Worth, TX
    Fort Worth, Texas 76104-4145, United States
  • Advances in Health, INC. | Houston, TX
    Houston, Texas 77030, United States
  • UTHealth Womens Research Program | Memorial City
    Houston, Texas 77054, United States
  • ClinRx Research, LLC
    Plano, Texas 75024, United States
  • The Woman's Place - Midlife Health
    Charlottesville, Virginia 22903, United States
  • Tidewater Clinical Research, Inc.
    Norfolk, Virginia 23456, United States
  • Northwest Clinical Research Center | Bellevue, WA
    Bellevue, Washington 98007, United States
  • Alta Clinical Research Inc | Edmonton, Canada
    Edmonton, Alberta T5A 4L8, Canada
  • IWK Health Centre | Department of Obstetrics and Gynaecology
    Halifax, Nova Scotia B3K 6R8, Canada
  • Ecogene 21
    Chicoutimi, Quebec G7H 0S7, Canada
  • GCP Research | Montreal, Canada
    Montreal, Quebec H1M 1B1, Canada
  • Clinique Ovo | R&D Department
    Montreal, Quebec H4P 2S4, Canada
  • Diex Recherche Sherbrooke Inc.
    Sherbrooke, Quebec J1L 0H8, Canada
  • Alpha Recherche Clinique | Val-Belair
    Val-Bélair, Quebec G3K 2P8, Canada
  • Diex Recherche Victoriaville Inc.
    Victoriaville, Quebec G6P 6P6, Canada
  • Diex Recherche Quebec Inc.
    Québec, G1V 4T3, Canada
  • Alpha Recherche Clinique | Lebourgneuf
    Québec, G2J 0C4, Canada
  • GynPorCentrum s.r.o.
    Krnov, 794 01, Czechia
  • MUDr. Martina Maresova Rosenbergova, gynekologie
    Pilsen, 301 00, Czechia
  • Gynekologie Studentsky dum s.r.o.
    Prague, 160 00, Czechia
  • GYNEVI s.r.o.
    Rokycany, 337 01, Czechia
  • Gynpraxetabor s.r.o.
    Tábor, 390 03, Czechia
  • Synexus Frankfurt Clinical Research Centre
    Frankfurt am Main, Hesse 60313, Germany
  • Praxis Hr. Dr. S. Fiedler
    Aachen, North Rhine-Westphalia 52074, Germany
  • Frauenärzte am Schloss Borbeck
    Essen, North Rhine-Westphalia 45355, Germany
  • Medplus Nordrhein
    Krefeld, North Rhine-Westphalia 47799, Germany
  • Synexus Leipzig Clinical Research Centre
    Leipzig, Saxony 04177, Germany
  • Praxis f. Gynäkologie und Geburtshilfe
    Bernburg, Saxony-Anhalt 6406, Germany
  • Frauenarztpraxis Dr. Inka Kiesche
    Halle, Saxony-Anhalt 06110, Germany
  • Femme Frauenarztpraxis
    Gera, Thuringia 7545, Germany
  • emovis GmbH
    Berlin, 10629, Germany
  • Synexus Berlin Clinical Research Centre
    Berlin, 12627, Germany
  • A.O.U. Policlinico Federico II Napoli
    Naples, Campania 80131, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Rome, Lazio 00168, Italy
  • Azienda Ospedaliera Ordine Mauriziano Di Torino
    Turin, Piedmont 10128, Italy
  • Azienda Ospedaliera Universitaria Integrata Verona_Borgo Trento - Ostetricia e Ginecologia B
    Verona, Veneto 37126, Italy
  • Kirkeparken Spesialistpraksis
    Fredrikstad, 1605, Norway
  • Medicus | Oslo, Norway
    Oslo, 161, Norway
  • Oslo University Hospital | Division of Obstetrics and Gynecology, Department of Research
    Oslo, 450, Norway
  • Medicus | Stavanger, Norway
    Stavanger, 4005, Norway
  • Medicus AS
    Trondheim, 7014, Norway
  • Gabinet Ginekologiczny Janusz Tomaszewski
    Bialystok, 15-224, Poland
  • CLINICAL MEDICAL RESEARCH Sp. z o. o.
    Katowice, 40-156, Poland
  • Centrum Medyczne Angelius Provita
    Katowice, 40-611, Poland
  • Vita Longa Sp. z o.o.
    Katowice, 40-748, Poland
  • Etyka Osrodek Badan Klinicznych
    Olsztyn, 10-117, Poland
  • Twoja Przychodnia - Szczecinskie Centrum Medyczne
    Szczecin, 71-500, Poland
  • Luz Saude | Hospital Beatriz Angelo - Centro de Investigacao Clinica
    Loures, Lisbon District 2674-514, Portugal
  • Hospital Santa Maria | Centro de Investigacao Clinica
    Missing, Lisbon District 1649-035, Portugal
  • Hospital Pedro Hispano | Clinical Research Center
    Matosinhos Municipality, Porto District 4464-513, Portugal
  • Luz Saude | Hospital da Luz Setubal - Clinical Research Department
    Setúbal, Setúbal District 2900-722, Portugal
  • Centro Hospitalar e Universitario de Coimbra, E.P.E. | Department of Gynecology
    Coimbra, 3000-075, Portugal
  • Centro Hospitalar de Lisboa Ocidental | Clinical Research Department
    Lisbon, 1449-005, Portugal
  • Centro Hospitalar Universitario do Porto | Servico de Investigacao Clinica
    Porto, 4050-651, Portugal
  • RC Medical
    Novosibirsk, 630091, Russia
  • Univerzitna nemocnica Bratislava, Nem. Sv. Cyrila a Metoda
    Bratislava, 851 07, Slovakia
  • GYNARIN, s.r.o.
    Fiľakovo, 986 01, Slovakia
  • ULMUS, s r.o.
    Hlohovec, 920 01, Slovakia
  • Nemocnica AGEL Kocice-Saca a.s.
    Kosice - Saca, 040 15, Slovakia

Showing the first 100 of 113 sites across 12 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Pinkerton JV, Simon JA, Joffe H, Maki PM, Nappi RE, Panay N, Soares CN, Thurston RC, Caetano C, Haberland C, Haseli Mashhadi N, Krahn U, Mellinger U, Parke S, Seitz C, Zuurman L. Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: OASIS 1 and 2 Randomized Clinical Trials. JAMA. 2024 Aug 22;332(16):1343-54. doi: 10.1001/jama.2024.14618. Online ahead of print. PubMed 39172446 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Jun 2023, 19 months.

Results were first posted in Feb 2026, 2 years 7 months after primary completion. A results delay was requested in May 2024.

Of 23 phase 3 interventional studies under Hot Flashes, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 29. This study's 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2021
First posted
Oct 29, 2021
StartActual
Oct 29, 2021
Primary completionActual
Jun 13, 2023
CompletionActual
Oct 10, 2023
Results delay requested
May 28, 2024
Results first posted
Feb 12, 2026
Last update
Feb 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05099159
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Oct 29, 2021
Start date
Oct 29, 2021
Primary completion
Jun 13, 2023
Completion
Oct 10, 2023
Results posted
Feb 12, 2026
Last update
Feb 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elinzanetant

Start the discussion